Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Third Harmonic Bio Inc. (THRD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: THRD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.39% | Avg. Invested days 43 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 242.79M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 4 | Beta 2.13 | 52 Weeks Range 3.18 - 16.02 | Updated Date 08/15/2025 |
52 Weeks Range 3.18 - 16.02 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.24 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.23 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -14.6% | Return on Equity (TTM) -19.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -25821453 | Price to Sales(TTM) - |
Enterprise Value -25821453 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.09 | Shares Outstanding 45127800 | Shares Floating 15603387 |
Shares Outstanding 45127800 | Shares Floating 15603387 | ||
Percent Insiders 9.11 | Percent Institutions 80.12 |
Upturn AI SWOT
Third Harmonic Bio Inc.
Company Overview
History and Background
Third Harmonic Bio, Inc. was founded in 2019. It is a clinical-stage biopharmaceutical company focused on developing and commercializing a highly selective oral therapy, donazolide (TJM2), for the treatment of chronic inducible urticaria (CIU) and other mast cell-mediated diseases.
Core Business Areas
- Pharmaceutical Development: Developing and commercializing donazolide (TJM2), a selective oral therapy targeting KIT receptors.
- Research and Development: Conducting research to identify and develop therapies for mast cell-mediated diseases.
Leadership and Structure
The leadership team includes key executives in research, development, and business operations. The company has a standard organizational structure for a biopharmaceutical company.
Top Products and Market Share
Key Offerings
- Donazolide (TJM2): Donazolide is Third Harmonic Bio's lead product candidate, an oral KIT inhibitor being developed for CIU. The company has not yet generated revenue from this product. Competitors include Xolair (Novartis/Genentech), Nucala (GSK), and other antihistamines.
Market Dynamics
Industry Overview
The biopharmaceutical industry is competitive and heavily regulated. It requires significant investment in R&D and faces risks related to clinical trial outcomes and regulatory approvals.
Positioning
Third Harmonic Bio aims to differentiate itself with its oral KIT inhibitor, targeting specific mast cell-mediated diseases. Its competitive advantage lies in potential efficacy and safety profile of Donazolide (TJM2).
Total Addressable Market (TAM)
The global chronic urticaria market is estimated to be worth billions of dollars annually. Third Harmonic Bio is positioned to capture a share of this market with its lead product donazolide (TJM2), if approved.
Upturn SWOT Analysis
Strengths
- Novel oral therapy (Donazolide)
- Targeting specific mast cell-mediated diseases
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on single product candidate
- Lack of commercial infrastructure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into other mast cell-mediated diseases
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies
Competitors and Market Share
Key Competitors
- NVS
- SNY
- GSK
- LLY
Competitive Landscape
Third Harmonic Bio faces competition from established pharmaceutical companies with marketed products for urticaria. The advantage lies in the potential efficacy and safety profile of an oral KIT inhibitor.
Growth Trajectory and Initiatives
Historical Growth: Since it is a recently-formed company, historical growth is based on raising capital and advancing donazolide (TJM2) through clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of donazolide (TJM2).
Recent Initiatives: Recent initiatives include advancing donazolide (TJM2) into Phase 2 clinical trials.
Summary
Third Harmonic Bio is a clinical-stage biopharmaceutical company with its lead product donazolide (TJM2) in development for CIU. Its success depends on positive clinical trial results and regulatory approval. The company faces competition from established pharmaceutical companies and needs to effectively manage its financial resources. Successful commercialization of donazolide (TJM2) would be a major step, though risks in the drug development process remain.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share information is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Third Harmonic Bio Inc.
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2022-09-14 | CEO & Director Ms. Natalie C. Holles | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://www.thirdharmonicbio.com |
Full time employees 31 | Website https://www.thirdharmonicbio.com | ||
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.